Britannia Life Sciences Balance Sheet Health
Financial Health criteria checks 2/6
Britannia Life Sciences has a total shareholder equity of CA$6.2M and total debt of CA$7.1M, which brings its debt-to-equity ratio to 113.5%. Its total assets and total liabilities are CA$22.8M and CA$16.5M respectively. Britannia Life Sciences's EBIT is CA$1.1M making its interest coverage ratio 0.9. It has cash and short-term investments of CA$977.2K.
Key information
113.5%
Debt to equity ratio
CA$7.06m
Debt
| Interest coverage ratio | 0.9x |
| Cash | CA$977.18k |
| Equity | CA$6.22m |
| Total liabilities | CA$16.54m |
| Total assets | CA$22.76m |
Recent financial health updates
Recent updates
Is Britannia Life Sciences (CSE:BLAB) Using Too Much Debt?
Feb 06
Britannia Life Sciences (CSE:BLAB) Shareholders Will Want The ROCE Trajectory To Continue
Mar 01Britannia Life Sciences (CSE:BLAB) Might Have The Makings Of A Multi-Bagger
Nov 14Returns At Britannia Life Sciences (CSE:BLAB) Appear To Be Weighed Down
Apr 19A Look At The Fair Value Of Britannia Life Sciences Inc. (CSE:BLAB)
Mar 13Financial Position Analysis
Short Term Liabilities: BLAB's short term assets (CA$2.9M) do not cover its short term liabilities (CA$11.5M).
Long Term Liabilities: BLAB's short term assets (CA$2.9M) do not cover its long term liabilities (CA$5.1M).
Debt to Equity History and Analysis
Debt Level: BLAB's net debt to equity ratio (97.8%) is considered high.
Reducing Debt: Insufficient data to determine if BLAB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BLAB has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BLAB is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 23% per year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/07 01:52 |
| End of Day Share Price | 2025/02/05 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Britannia Life Sciences Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.